Êü¼ÍÀþÍøÍѵ»½Ñ¥Ç¡¼¥¿¥Ù¡¼¥¹¤Î¥á¥¤¥ó¥Ú¡¼¥¸¤Ø

ºîÀ®¡§ 2003/12/16 Åâß·¡¡¹îÇ·

¥Ç¡¼¥¿Èֹ桡¡¡¡¡¡§030255
繤¬¤ó¤Ø¤Î½ÑÃæ¾È¼Í
ÌÜŪ¡¡¡¡¡¡¡¡¡¡¡¡¡§½ÑÃæ¾È¼ÍÃæ¿´¤Ë繤¬¤ó¤Î¼£ÎÅÊý¿Ë¤ÈÌäÂêÅÀ¤Ë¤Ä¤¤¤Æ¤Î²òÀâ
Êü¼ÍÀþ¤Î¼ïÊÌ¡¡¡¡¡§¥¨¥Ã¥¯¥¹Àþ,ÅÅ»Ò
Êü¼ÍÀþ¸»¡¡¡¡¡¡¡¡¡§XÀþ¡¢ÅÅ»ÒÀþ
±þÍÑʬÌî¡¡¡¡¡¡¡¡¡§°å³Ø,¼£ÎÅ

³µÍס¡¡¡¡¡¡¡¡¡¡¡¡§
¡¡¸üÀ¸Ï«Æ¯¾Ê¤ÎÅý·×¤Ë¤è¤ë¤È繤¬¤ó¤Î»àË´¼Ô¿ô¤Ï¡¢2002ǯ¤Ç2Ëü¿Í¤ò±Û¤¨¡¢1985ǯ¤ËÈæ³Ó¤·¤ÆÌó2ÇܤËÁý²Ã¤·¤Æ¤¤¤ë¡£ÌäÂê¤ÏØí´µÎ¨¤Î³ä¤Ë»à˴Ψ¤¬¹â¤¯¡¢¶áǯÀ¸Â¸´ü´Ö¤Ë¤Ä¤¤¤Æ¤Ï¼ã´³²þÁ±¤·¤¿¤¬¡¢¼£ÌþΨ¤ÏËؤɲþÁ±¤µ¤ì¤Æ¤¤¤Ê¤¤¡£ç¹¤¬¤ó¤Ïͽ¸åÉÔÎɤǤ¢¤ê¡¢Î×¾²¾É¾õ¤¬½Ð¤Ë¤¯¤¯¡¢¶É½êµÚ¤Ó´Îž°ÜÅù¤Ø¤Î¿ÊŸ¤¬Áá´ü¤Ëµ¯¤³¤ê¤ä¤¹¤¯¡¢Êü¼ÍÀþ¤ä¹³¤¬¤óºÞ¤Î´¶¼õÀ­¤¬Îɤ¯¤Ê¤¤¤Ê¤É¿¤¯¤ÎÍýͳ¤¬µó¤²¤é¤ì¤ë¡£ÀÚ½üÎã¤Ç¤âŷ¤¬£±­Ñ¤ò±Û¤¨¤ë¤Èͽ¸å¤¬°­¤¯¤Ê¤ë¤È¤µ¤ì¤Æ¤¤¤ë¡£ç¹¤¬¤ó¤¬ºÇ¶áÁý²Ã·¹¸þ¤Ë¤¢¤ë¤Î¤Ç¡¢²è´üŪ¤Ê¼£ÎÅË¡¤¬´üÂÔ¤µ¤ì¤ë¡£

¾ÜºÙÀâÌÀ¡¡¡¡¡¡¡¡¡§
£±¡¥ 繤¬¤ó¤Î¼£ÎÅ
¡¡ç¹¤¬¤ó¤Î¼£ÎŤϸµÍèÀÚ½ü¤¬Âè°ìÁªÂò¤Ç¤¢¤Ã¤¿¡£¤·¤«¤·¼£ÌþÀÚÃǤò¹Ô¤Ã¤Æ¤â¡¢¶É½êµÚ¤Ó±ó³ÖºÆȯ¤¬Â¿¤¯¡¢Êä½õÎÅË¡¤ÎɬÍ×À­¤¬À⤫¤ì¤ÆÍ褿¡£ºÇ¶á¤Î²¤½£¤ÎÎ×¾²»î¸³¤«¤é¡¢Êä½õÎÅË¡¤È¤·¤Æ¤Ï²½³ØÎÅË¡¤ÎÍ­ÍÑÀ­¤¬ÌÀ¤é¤«¤Ë¤µ¤ì¤¿¡£°ìÊýÈóÀÚ½ü繤¬¤ó¤Ë¤Ä¤¤¤Æ¤ÏÊü¼ÍÀþ¼£Îšܲ½³ØÎÅË¡¤Ë¤è¤ë¼£ÎŤ¬É¸½à¤È¤µ¤ì¤Æ¤¤¤ë¤¬¡¢¤Þ¤À¤³¤Î¼£ÎÅË¡¤Ë¤Ä¤¤¤Æ¤Ï»î¸³Åª¤ÊÃʳ¬¤Ç¤¢¤ë¡£
¡¡½ÑÃæ¾È¼Í¤Ë¤Ä¤¤¤Æ¤ÏÊü¼ÍÀþ´¶¼õÀ­¤Î¹â¤¯¤Ê¤¤ç¹¤¬¤ó¤Ï³°Éô¾È¼Í¤Î¤ß¤Ç¶É½êÀ©¸æ¤òÆÀ¤ë¤³¤È¤ÏÎ㳰Ū¤Ç¤¢¤ë¤³¤È¤«¤é¡¢¶É½êÀ©¸æ¤ò¹â¤á¤ë¤¿¤á¤Ë¤ÏÀµ¾ïÁÈ¿¥¤Ø¤ÎÀþÎ̤òÁý¤ä¤µ¤º¤Ë¡¢³°Éô¾È¼Í¤ËÄɲ乤ë·Á¤ÇÍѤ¤¤ì¤Ð¡¢Í­Ë¾¤Ç¤¢¤ë¤È¹Í¤¨¤é¤ì¤Æ¤¤¤ë¡£

£²¡¥ 繤¬¤ó½ÑÃæ¾È¼Í¤Î¼ÂºÝ
¡¡¶ð¹þɱ¡¤Ç¤Î繤¬¤ó¤Î¼£ÎÅÊý¿Ë¤ò¼¨¤¹¡£¡Ê¿Þ1¡Ë¡£¤Þ¤º½ÑÁ°¸¡º÷¤Ç±ó³Öž°Ü¤Î̵ͭ¤ò¥Á¥¨¥Ã¥¯¤·¡¢±ó³Öž°Ü¤¬¤Ê¤¯¡¢¼ê½Ñ¤ËÂѤ¨¤é¤ì¤ë¾ì¹ç¡¢³«Ê¢¼ê½Ñ¤ò¹Ô¤¦¡£³«Ê¢»þÀÚ½ü¤Î²ÄÈݤòȽÄꤷ¡¢ÀÚ½ü²Äǽ¤ÇÍ­¤ì¤ÐÀÚ½ü¤ò¹Ô¤¤¡¢Ä¾¸å¤Ë½ÑÃæ¾È¼Í¤ò¹Ô¤¤¡¢ÉÔǽ¤Ç¤¢¤ì¤Ð¡¢½Ñ¸å¤Ëµ¯¤³¤ëÄ̲á¾ã³²¤ÎͽËɤΤ¿¤á¡¢¾Ã²½´É¤Î¥Ð¥¤¥Ñ¥¹¤ò¹Ô¤¤¡¢¤½¤Î¸å½ÑÃæ¾È¼Í¤ò¹Ô¤¦¡£½Ñ¸å¤Ë³°Éô¾È¼Í¤ò¹Ô¤¦¡£
¡¡ÀÚ½ü¤Î¾ì¹ç¤ÏÀÚ½ü¸å¡¢¾Ã²½´É¤Î¥Ð¥¤¥Ñ¥¹¤Î¾ì¹ç¤Ï¼ðáç¤òϪ½Ð¤·¤Æ¡¢¼ê½Ñ¼¼¤«¤é¾È¼Í¼¼¤Þ¤ÇÈÂÁ÷¤·¡¢¼£ÎÅÁõÃ֤ΤȤ³¤í¤Ç¡¢¾È¼ÍÈϰϤò·èÄꤷ¤Æ¡¢¾È¼ÍÅû¤ò¼£ÎÅÁõÃ֤˸ÇÄꤷ¤Æ¡¢¼£ÎŤò³«»Ï¤¹¤ë¡Ê¿Þ2¡Ë¡£¾È¼Í¤Ï繤¬¤óÀÚ½ü¸å¤Î¾ì¹ç¤Ï¼ðáç¤Î¸ºß¤·¤¿Éô°Ì¤ÈÊ¢¹ÐÆ°Ì®¡¢µÚ¤Ó¾åIJ´ÖËìÆ°Ì®¤Îº¬Éô¤ò´Þ¤àÈϰϤˡ¢ÈóÀÚ½ü¤Î¾ì¹ç¤Ë¤Ï繤¬¤ó¤½¤Î¤â¤Î¤ËÂФ·¤Æ»Ü¹Ô¤µ¤ì¤ë¡£¾È¼ÍÃæ¤Ï¼¼³°¤«¤é¥Æ¥ì¥Ó¥â¥Ë¥¿¤Ç´µ¼Ô¤È¥Ð¥¤¥¿¥ë¤ò´Ñ»¡¤¹¤ë¡£20Gy¤Î¾È¼Í»þ´Ö¤Ï³µ¤Í5ʬÄøÅ٤Ǥ¢¤ë¡£¶ð¹þɱ¡¤Ç¤Ï¾È¼Í¤Ï¼ê½Ñ¼¼¤Î³°¤ò½Ð¤Æ¡¢100¥á¡Ý¥È¥ëÄøÎ¥¤ì¤¿¡¢¾È¼Í¼¼¤ØÈÂÁ÷¤¹¤ë·Á¤Ç¹Ô¤ï¤ì¤ë¤¬¡¢¼ê½Ñ¼¼¤ò½Ð¤Æ¤«¤é¡¢µ¢¼¼¤¹¤ë¤Þ¤Ç¤Î½êÍ×»þ´Ö¤ÏÌó30ʬ¤Ç¤¢¤ë¡£


¿Þ1¡¡ÅÔΩ¶ð¹þɱ¡¤Ë¤ª¤±¤ë繤¬¤ó¤Î¼£ÎÅÊý¿Ë



¿Þ2¡¡½ÑÃæ¾È¼ÍÊýË¡

£³¡¥ 繤¬¤ó½ÑÃæ¾È¼Í¤Î¼£ÎÅÀ®ÀÓ
¡¡¶ð¹þɱ¡¤Ç¤Ï³«±¡°ÊÍèÌó250Îã¤Î繤¬¤ó¾ÉÎã¤Ë½ÑÃæ¾È¼Í¤ò¹Ô¤Ã¤Æ¤¤¤ë¡£1983¡Á1998ǯ¤Þ¤Ç¤Î108Îã¤ËÂФ¹¤ëÀ®ÀӤǤϡ¢Á´Îã¤ÎÊ¿¶ÑÀ¸Â¸´ü´Ö¤¬11.3¥«·î¡¢1ǯÀ¸Â¸Î¨¡¢2ǯÀ¸Â¸Î¨¤¬46.7%,17.4%¤Ç¤¢¤Ã¤¿¡£ÀÚ½üÎã¤Ç¤ÏÊ¿¶ÑÀ¸Â¸´ü´Ö,1ǯÀ¸Â¸Î¨¡¢2ǯÀ¸Â¸Î¨¤¬12.4¥«·î¡¢53.3%,24.1%,ÈóÀÚ½üÎã¤Ç¤Ï³Æ¡¹10.3¥«·î¡¢39.7%,8.2%¤Ç¤¢¤Ã¤¿¡£ÀÚ½üÎã¤Î¤¦¤Á¼£ÌþÀÚ½üÎã¤Ï³Æ¡¹17.4¥«·î¡¢71.4%,38.7%¤Ç¡¢Èó¼£ÌþÀÚ½üÎã¤Ï³Æ¡¹10.2¥«·î¡¢44.2%,16.6%¤Ç¤¢¤Ã¤¿¡£Èó¼£ÌþÀÚ½üÎã¤ÈÈóÀÚ½üÎã¤Îͽ¸å¤Ëº¹¤¬Ç§¤á¤é¤ì¤Ê¤«¤Ã¤¿¡Ê¿Þ3¡Ë¡£30Æü°ÊÆâ¤Î»àË´¤Ï£±Îã¤â¤Ê¤«¤Ã¤¿¡£»à°ø¤Ï´Îž°Ü¤Ë¤è¤ë´ÎÉÔÁ´¤¬ºÇ¤â¿¤«¤Ã¤¿¡£


¿Þ3¡¡Èó¼£ÌþÀÚ½ü¤ÈÈóÀÚ½üË¡¤Ë¤è¤ëÀ¸Â¸Î¨



¥³¥á¥ó¥È¡¡¡¡¡¡¡¡¡§
¸½ºß½ÑÃæ¾È¼Í¤ËGemcitabineÅù¤Î¿·µ¬¹³¤¬¤óºÞ¤ÎÊ»ÍѤ䡢Äã»ÀÁǺÙ˦Áý´¶ºÞ¤ÎÊ»ÍÑÅù¤¬»î¤ß¤é¤ì¡¢¤µ¤é¤Ê¤ë¼£ÎÅÀ®ÀӤθþ¾å¤¬Ìܻؤµ¤ì¤Æ¤¤¤ë¡£ÌäÂêÅÀ¤È¤·¤Æ¤Ï½ÑÃæ¾È¼Í¤¬³°²Ê¡¢Êü¼ÍÀþ²Ê¡¢Ëã¿ì²Ê¤Î¶¨Îϲ¼¤Ç¹Ô¤ï¤ì¤ëɬÍפ¬¤¢¤ê¡¢¸½ºßÂ礭¤ÊÂç³Øɱ¡¤Ç¤µ¤¨¤â¡¢ÀßÈ÷¡¢ÂÎÀ©¤È¤â¤ËÀ°¤ï¤º¤Ë¹Ô¤ï¤ì¤Æ¤¤¤ë¸½¼Â¤¬¤¢¤ë¤È¤¤¤¦ÅÀ¤Ç¤¢¤ë¡£¤Þ¤¿Î×¾²Åª¤Ë¤Ï´Îž°Ü¤Î¹îÉþ¤¬É¬¿Ü¤È¹Í¤¨¤é¤ì¤Æ¤¤¤ë¡£¤Þ¤¿ç¹¤¬¤ó¤Ï°×¿Ê¹ÔÀ­¤«¤Ä¼£ÎÅÄñ¹³À­¤Ê¤¿¤á¡¢¤Ê¤«¤Ê¤«¼£ÎŤÎÀ®¸ùÎ㤬¸«¤é¤ì¤Ê¤¤¡£º£¸å¤è¤ê¤è¤¤½¸³ØŪ¼£ÎÅË¡¤ò¸«½Ð¤·¡¢¼£ÎÅÀ®ÀÓ¤¬²þÁ±¤¹¤ë¤³¤È¤¬ÂÔ¤¿¤ì¤ë¡£

¥­¡¼¥ï¡¼¥É¡§ç¹¤¬¤ó, Êü¼ÍÀþ¼£ÎÅ, Êü¼ÍÀþ´¶¼õÀ­, ½ÑÃæ¾È¼Í, ³°Éô¾È¼Í, Pancreatic Cancer, Radiation Therapy, Radiosensitivity, Intraoperative Radiation Therapy, External Irradiation
ʬÎॳ¡¼¥É¡§030201

Êü¼ÍÀþÍøÍѵ»½Ñ¥Ç¡¼¥¿¥Ù¡¼¥¹¤Î¥á¥¤¥ó¥Ú¡¼¥¸¤Ø